You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

177Lu-PSMA

Showing 1 - 25 of 733
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Prostate Cancer Trial in Nanjing (177Lu-PSMA-0057)

Recruiting
  • Metastatic Prostate Cancer
  • Nanjing, Jiangsu, China
    Nanjing First Hospital
Sep 17, 2023

Cancer Trial in Meldola, Cesena ([177Lu]Lu-PSMA I&T)

Not yet recruiting
  • Cancer
  • [177Lu]Lu-PSMA I&T
  • Meldola, Forlì, Italy
  • +1 more
May 10, 2023

Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Mar 1, 2023

Patients With Metastatic Castration-resistant Prostate Cancer Trial (177Lu-PSMA-617 PET scan)

Not yet recruiting
  • Patients With Metastatic Castration-resistant Prostate Cancer
  • 177Lu-PSMA-617 PET scan
  • (no location specified)
Nov 13, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 6, 2022

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (177Lu-PSMA-617, PSMA-11)

No longer available
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 12, 2023

Cancer, Prostate Cancer, Metastatic Cancer Trial (177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended

Not yet recruiting
  • Cancer
  • +3 more
  • 177Lu-PSMA-I&T - escalating renal absorbed dose
  • 177Lu-PSMA-I&T - recommended phase 2 regime
  • (no location specified)
Jun 14, 2023

High Grade Glioma Trial (177Lu-PSMA I&T)

Not yet recruiting
  • High Grade Glioma
  • 177Lu-PSMA I&T
  • (no location specified)
Dec 1, 2022

Prostate Cancer Trial (AAA617)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Mar 27, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Nov 10, 2022

Prostate Cancer Trial in New York (177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT))

Active, not recruiting
  • Prostate Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Nov 17, 2022

Prostate Cancer Trial ([177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy)

Not yet recruiting
  • Prostate Cancer
  • [177Lu]Lu-PSMA I&T
  • Stereotactic Radiotherapy
  • (no location specified)
May 30, 2023

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • mCRPC
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Jul 20, 2022

Prostate Cancer Trial in Sapporo city, Kanazawa-city (177Lu-PSMA-617, 68Ga-PSMA-11, Best supportive/best standard of care)

Recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • +2 more
  • Kashiwa, Chiba, Japan
  • +6 more
Jan 23, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Metastatic Clear Cell Renal Cell Carcinoma, With Positive PSMA Expression at Tumor Sites Trial (177Lu-PSMA-1

Not yet recruiting
  • Metastatic Clear Cell Renal Cell Carcinoma
  • With Positive PSMA Expression at Tumor Sites
  • 177Lu-PSMA-1 (radiopharmaceutical)
  • (no location specified)
Sep 26, 2023

Metastatic Hormone Naive Prostate Cancer Trial in Australia (177Lu-PSMA-617, Docetaxel)

Recruiting
  • Metastatic Hormone Naive Prostate Cancer
  • Sydney, New South Wales, Australia
  • +4 more
Nov 4, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in San

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +6 more
  • San Francisco, California
    University of California, San Francisco
Sep 8, 2022

Oligometastatic Prostate Cancer Trial (177Lu-PSMA)

Not yet recruiting
  • Oligometastatic Prostate Cancer
  • 177Lu-PSMA
  • (no location specified)
Sep 26, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Seattle

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Biopsy
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Nov 17, 2023

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in San Francisco

Active, not recruiting
  • Castration Levels of Testosterone
  • +6 more
  • Lutetium Lu 177-PSMA-617
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Apr 11, 2022

Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)

Not yet recruiting
  • Prostatic Neoplasms
  • Castration-Resistant
  • (no location specified)
Dec 1, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Image Guided Biopsy
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jun 17, 2022